modern biotechnology dr nataporn chanvarasuth
TRANSCRIPT
![Page 1: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/1.jpg)
Technical Session VPolicy and Institutional Frameworks for Hi-tech Innovation Systems
Modern biotechnology
![Page 2: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/2.jpg)
Year 2030 Bioeconomy
OECD: The bioeconomy in 2030 is likely to involve three elements: 1. advanced knowledge of genes and complex cell processes2. renewable biomass3. integration of biotechnology applications across sectors.
OECD = the Organization for Economic Co-operation and Development
![Page 3: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/3.jpg)
Bioeconomy: Born from necessity : Need innovation to meet the challenges
![Page 4: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/4.jpg)
Energy crisis
Climate change &Resource crisis
Emerging diseases Well being & Aging people
pollution
Biotechnology: the fourth wave to solve the global problems
Green products
Green process
Plants: high production + resistant traitsBioremediation
Diagnostic deviceMedical systemVaccine
NutraceuticalFunctional food
![Page 5: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/5.jpg)
Specific Characteristics of Biotech Business
• Knowledge based industry
• Diverse benefit
• High investment and long-term return (~3-10 years)
• SMEs (Size < 100 employees)
• High control & regulation
• Market oriented
![Page 6: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/6.jpg)
http://www.slideshare.net/danielsatinsky/boston-innovation-ecosystem-st-petersburg
Heart of innovation ecosystem is the regular and constant interaction bringing great science with entrepreneurs
To help reduce some risks, government needs to provide suitable supports: Innovation ecosystem
![Page 7: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/7.jpg)
http://www.biowin.org/biowin/en/5408-home.html
To create innovation ecosystem, Wallonia region identify 6 competitive clustersStrategy of the BioWin cluster (health cluster)
BioWin is a not-for-profit organization. This unit is governed by a governing board, assisted by a permanent operational team.
BioWin gathers more than500 members:• 130 companies (125 SMEs and 5 Global leaders: Baxter, GSK, IBA, UCB, and Eurogentec-Kaneka • 400 research centers, 5 universities
2x2 model for innovation
![Page 8: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/8.jpg)
Open Innovation• Key elements: networking, collaboration with partners, competitors, universities, and users • proactive intellectual property management• R&D to obtain competitive advantage
“Partners with others to create the most and the best ideas in the industry”
“ Make profit from the other’s use of our IP, and also buy others’ IP when it advances our business model”
![Page 9: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/9.jpg)
Specify future niche direction from own strength and alsoNation’s master plan
USA - medical innovation focusing human health- food & agriculture- biobased industry using industrial enzyme
Japan- medical technology- in vitro diagnostics- drug discovery- medical device, functional food
Taiwan - Hub of clinical trial in Asia- focus on traditional Chinese herbal medicines
Process to identify niche direction1. Select innovation/capability focus2. Uncover customer needs3. Priority customer needs4. Develop strategy
![Page 10: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/10.jpg)
Provide suitable environment … vision with commitment
USA- provide tax incentives for SMEs - support source of money (venture capital funding)
Malaysia- Create Bill of Guarantees for biotech companies to ensure IP protection and freedom to import capital and labor- Create BiotechCorp as a convenient one-stop shop for biotech companies providing funding and assistance with IP, immigration, regulation, and employment matters- Launched the Biotechnology Commercialization Fund
Singapore- Commercialization framework via Exploit Technologies (business arm of A*STAR) bridging R&D to industry- government incentives ex. Match $ per $- world-class R&D infrastructure
Suitable environment• budget• infrastructure• host • etc.
![Page 11: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/11.jpg)
Set up systems to expedite technology transfer and commercialization
Soft services to serve researchers and startups• IP protection• incubation: coaching & mentoring• commercialize process & marketing
![Page 12: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/12.jpg)
https://www.bio.org/sites/default/files/GPP-FINAL-2-1-2013.pdf
Provide a transparent and predictable regulatory approval process
Singapore- Integration among govt. and private agencies: : Biomedical Research council: Singapore Economic Development Board (EDB): Biomedical Science Group: Ministry of Health (MOH),and Bio*One Capital: A*STAR Joint Council to support interdisciplinary researchTaiwan
- Multiministerial efforts supervised by Science and Technology Advisory Group of the Executive Yuan (Cabinet): National Science Council + the Ministry of Economic Affairs
![Page 13: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/13.jpg)
Maintain transparent, non-discriminatory, competitive, and commercially viable market for biotech productsUSA launches BioPreferred program to certify
biobased products (government procurement)
• managed by the US Department of Agriculture (USDA) • to increase the purchase and use of bio-based products • 2 major parts of the program: - mandatory purchasing requirements for federal agencies and their contractors - voluntary labeling initiative for bio-based products
![Page 14: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/14.jpg)
Thai Government Policy to support STI
Increase R&D investment to 1% of GDPRatio of public and private = 30:70
Support Maga projectsUse Thai innovation for government procurement
Create innovation society - STEM education- talent mobility
Improve law & regulation to push R&D for commercialization
Develop infrastructure for science, technology, and innovation
![Page 15: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/15.jpg)
http://unctad.org/meetings/en/Presentation/ecn162015p15_Durongkaveroj_en.pdf
![Page 16: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/16.jpg)
http://unctad.org/meetings/en/Presentation/ecn162015p15_Durongkaveroj_en.pdf
![Page 17: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/17.jpg)
Area: 80 AcresSpace: 140,000 m2
Types of space: Incubator units, wet/dry labs, long-term leased land
At present: 60 companies, 20 incubatees
Thailand Science ParkThailand Science Park
![Page 18: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/18.jpg)
Infrastructure for Knowledge Business
Convention CenterMulti-tenant Incubator
BuildingGreenhouse
Pilot PlantNational Centers
![Page 19: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/19.jpg)
Thailand Science Park - Phase 2
• Four integrated towers• Gross area of around 127,000 sq.m., Net area of 72,000 sq.m.• 40,000 sq.m. allocated for private companies• Clean room, sensitive lab, heavy equipment areas available
![Page 20: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/20.jpg)
![Page 21: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/21.jpg)
NSTDA: Linkage between R&D and Business
![Page 22: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/22.jpg)
![Page 23: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/23.jpg)
![Page 24: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/24.jpg)
Infrastructure & Facility
![Page 25: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/25.jpg)
NSTDA’s soft services
![Page 26: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/26.jpg)
http://unctad.org/meetings/en/Presentation/ecn162015p15_Durongkaveroj_en.pdf
![Page 27: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/27.jpg)
![Page 28: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/28.jpg)
![Page 29: Modern biotechnology Dr Nataporn Chanvarasuth](https://reader031.vdocument.in/reader031/viewer/2022021813/588718b21a28abf2228b78f7/html5/thumbnails/29.jpg)
AYUBOVON
KHOB KHUN KHA